These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 19918163

  • 1. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
    Muzaffar M, Taj A, Ratnam S.
    Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
    [Abstract] [Full Text] [Related]

  • 2. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [Abstract] [Full Text] [Related]

  • 3. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
    Aimoto M, Yamane T, Inoue A, Momose D, Moriguchi-Aimoto R, Wada-Inoue E, Okamoto S, Koh H, Nakane T, Takeoka Y, Akahori-Nakamae M, Nishiki-Kosaka S, Terada Y, Nakamae H, Koh KR, Nakao T, Ohsawa M, Hino M.
    Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
    [Abstract] [Full Text] [Related]

  • 4. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD, Barros V, Keitel E, Bittar AE, Ferrera des Santos A, Roithmann S.
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [Abstract] [Full Text] [Related]

  • 5. [Epstein-Barr virus-associated posttransplant lymphoproliferative disease after renal transplantation].
    Matsubara E, Yakushijin Y, Nomura T, Iwamasa K, Narumi H, Sakai I, Yasukawa M, Fujita S, Hato T, Ohshima K, Uno M.
    Rinsho Ketsueki; 2002 Oct; 43(10):949-53. PubMed ID: 12462032
    [Abstract] [Full Text] [Related]

  • 6. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ.
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [Abstract] [Full Text] [Related]

  • 7. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, Levi D, Nery JR, Cirocco RE, Gelman B, Ruiz P, Tzakis AG.
    Transplantation; 2002 Oct 15; 74(7):1000-6. PubMed ID: 12394845
    [Abstract] [Full Text] [Related]

  • 8. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S.
    Clin Transplant; 2003 Oct 15; 17(5):417-22. PubMed ID: 14703923
    [Abstract] [Full Text] [Related]

  • 9. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 15; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 10. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD, Hunger SP, Braylan RC, Dharnidharka VR.
    Transpl Infect Dis; 2008 Dec 15; 10(6):426-30. PubMed ID: 18657087
    [Abstract] [Full Text] [Related]

  • 11. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J.
    Transpl Int; 2014 Sep 15; 27(9):956-65. PubMed ID: 24964147
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct 15; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 13. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov 15; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 14. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
    Cornejo A, Bohnenblust M, Harris C, Abrahamian GA.
    Cancer Chemother Pharmacol; 2009 Sep 15; 64(4):857-60. PubMed ID: 19588139
    [Abstract] [Full Text] [Related]

  • 15. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
    Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS.
    Pediatr Transplant; 2004 Feb 15; 8(1):87-90. PubMed ID: 15009846
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant Lymphoproliferative Disorder--a case of late-onset T-cell lymphoma after failed renal transplant.
    Dalal P, Bichu P, Dhawan V, Ariyamuthu V, Malhotra K, Misra M, Khanna R.
    Adv Perit Dial; 2012 Feb 15; 28():94-6. PubMed ID: 23311222
    [Abstract] [Full Text] [Related]

  • 17. Brain tumor as an unusual presentation of posttransplant lymphoproliferative disorder.
    Azarpira N, Torabineghad S, Rakei M.
    Exp Clin Transplant; 2009 Mar 15; 7(1):58-61. PubMed ID: 19364315
    [Abstract] [Full Text] [Related]

  • 18. Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin.
    Khalpey Z, Miller DV, Schmitto JD, Kushwaha SS.
    Transplant Proc; 2011 Jun 15; 43(5):1893-9. PubMed ID: 21693296
    [Abstract] [Full Text] [Related]

  • 19. Evolution of PTLD following renal transplantation in a child.
    Markert E, Siebolts U, Habbig S, Odenthal M, Dienes HP, Stippel DL, Hoppe B, Wickenhauser C.
    Pediatr Transplant; 2009 May 15; 13(3):379-83. PubMed ID: 19017284
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 May 15; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.